Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies
2 other identifiers
interventional
2,300
0 countries
N/A
Brief Summary
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2026
Typical duration for phase_3
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2026
CompletedFirst Posted
Study publicly available on registry
August 27, 2026
CompletedStudy Start
First participant enrolled
September 2, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2030
Study Completion
Last participant's last visit for all outcomes
October 31, 2030
August 27, 2026
August 1, 2026
4.2 years
August 25, 2026
August 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants treated
Up to approximately 28 days after last dose of deucravacitinib
Study Arms (1)
Deucravacitinib Arm
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.
You may not qualify if:
- Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2026
First Posted
August 27, 2026
Study Start (Estimated)
September 2, 2026
Primary Completion (Estimated)
October 31, 2030
Study Completion (Estimated)
October 31, 2030
Last Updated
August 27, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html